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with endovascular modality
6 mos 12 mos 18 mos 24 mos 30 mos
Primary patency
BPG
65.6  8.4 51.6  9.1 25.8  8.3 22.1  7.9 22.1  7.9
Primary patency
No BPG
93.7  2.2 75.4  4.3 64.7  4.9 60.2  5.2 58.1  5.5
Primary patency P
Values
.0001 .0001 .0001 .0001 .0001
Primary assisted
patency BPG
87.3  6.0 75.9  8.0 70.5  9.1 65.1  9.9 65.1  9.9
Primary assisted
patency No
BPG
96.8  1.6 90.9  2.8 87.1  3.4 83.8  4.0 79.5  4.8
Primary assisted
patency P
Values
.031 .025 .031 .023 .039
Secondary patency
BPG
90.4  5.3 90.4  5.3 83.9  7.9 77.5  9.6 77.5  9.6
Secondary patency
No BPG
98.4  1.1 96.4  1.8 94.8  2.4 91.3  3.3 91.3  3.3
Secondary patency
P values
.03 .13 .06 .05 .05
BPG, Bypass grafting.
Long-Term Outcomes of Diabetic Patients Undergoing Endovascular
Infrainguinal Interventions
Abularrage CJ, Conrad MF, Crawford RS, et al
Objectives: Diabetes has traditionally predicted poor outcomes after
lower extremity revascularization for peripheral vascular disease (PVD). The
purpose of this studywas to assess the influence of diabetes on long-termoutcomes
of percutaneous translumininal angioplasty (PTA) in patients with PVD.
Methods: From January 2002 to December 2007, 1075 patients
underwent PTA. Endpoints including primary patency (PP), assisted pa-
tency (AP), limb salvage, and survival were evaluated in the entire cohort, as
well as in diabetic (DM) and non-diabetic (non-DM) patients, using Kaplan-
Meier and Cox regression analyses.
Results: There were 533 DM and 542 non-DM patients. Significant
clinical and demographic features are summarized in the Table. Median
follow-up was 34 months. In the entire cohort, the five-year PP was 42% 
2.4%, AP was 81%  2.0%, limb salvage was 89%  1.6%, and survival was
60%  2.2%. On univariate analysis, diabetes was associated with inferior
five-year PP (DM: 37%  3.4% vs. non-DM: 46%  3.3%, P .009), limb
salvage (84% 2.6% vs. 93% 1.8%, P .0001), and survival (52% 3.2%
vs. 68%  2.9%, P  .0001). Assisted patency did not differ between DM
and non-DM (P  .18). In the entire cohort, DM (1.25; [1.01-1.54]; P 
.04), single vessel peroneal runoff (1.54; [1.16-2.08]; P .003), and dialysis
(1.59; [1.10-2.33]; P  .02) were associated with decreased PP on multi-
variate analysis. DM was also an independent predictor of death after PTA
(1.32; [1.02-1.67]; P  .03). Critical limb ischemia and dialysis were the
only variables on multivariate analysis to predict both limb loss and death.
Conclusions: Diabetes is an independent predictor of decreased PP
and death after PTA. Although acceptable assisted patency rates can be
achieved with close surveillance and reintervention, long-term limb salvage
and survival remain inferior in the diabetic population due to a more severe
cardiovascular risk profile and clinical presentation.
Table. Clinical and demographic features
DM Non-DM P
Male gender 368 (69%) 323 (60%) .001
Coronary artery disease 368 (69%) 293 (54%) .0001
Dialysis 56 (11%) 22 (4%) .0001
Critical limb ischemia 284 (53%) 155 (24%) .0001
Single vessel runoff 205 (38%) 126 (23%) .0001
Multi-level intervention 125 (23%) 83 (15%) .0007
Isolated tibial intervention 58 (11%) 31 (6%) .002
DM, Diabetic.
Outcomes of Endoluminal Re-intervention for Recurrent Disease after
Percutaneous Iliac Angioplasty and Stenting
Davies MG, Bismuth J, Naoum J, Houssan H, Peden EK, Lumsden ABObjectives: Endovascular therapy for symptomatic atherosclerotic iliac
artery stenosis is common but is associated with a significant restenosis rate.This study evaluates the outcomes of percutaneous therapy for symptomatic
restenosis (50% on angiography) after iliac intervention at a national
academic medical center.
Methods: We performed a retrospective analysis of records from
patients who underwent endovascular intervention for symptomatic athero-
sclerotic iliac artery stenosis and were followed by duplex ultrasound be-
tween January 1990 and January 2009.
Results: Eight hundred seventy-nine patients underwent 1444 iliac
artery interventions. One hundred fifty-six vessels restenosed with an actuarial
restenosis rate of 20%  2% at five years. Presenting symptoms, angioplasty
alone, a concurrent occluded superficial femoral artery (SFA), and increasing
complexity of the iliac intervention were associated with restenosis. One
hundred forty of these restenoses (90%) were associated with recurrent
symptoms. One hundred nine (78%) underwent repeat angioplasty and 31
underwent bypass surgery. The remainder were observed. The 109 percu-
taneous interventions were performed in  patients (57%male; average age,
58 years; range, 38-87 years). Eighty-five percent had hypertension, 76%
had hyperlipidemia, 54% had metabolic syndrome, 41% were considered
diabetic, and 17% had chronic renal insufficiency (eGFR60). There was a
1% technical failure rate. Comparisons of demographics, presenting symp-
toms, and outcomes between those patients undergoing intervention for a
primary lesion and those for a recurrent lesion are shown in the Table. By
Cox proportional hazards and multivariate analysis, presenting symptoms,
female gender, and eGFR 60ml negatively influenced cumulative patency
of recurrent lesions. An occluded SFA but not TASC lesion negatively
influences cumulative patency of recurrent lesions. Restenosis and recurrent
symptoms were tightly associated
Conclusions: Percutaneous re-intervention for iliac artery restenosis is
safe and effective with equivalent outcomes to primary intervention. The
patients are more likely to be younger and of female gender than patients
presenting for primary intervention. Both patency and functional outcomes
after re-intervention are worse than primary interventions.
Table. Demographic variables and outcomes
Primary Recurrent P value
Gender (% male) 61 57 ns
Age (mean  SD; years) 65  12 58  11 ns
30-day mortality (%) 1 1 ns
Morbidity (%) 4 4 .05
Cumulative patency (% patent)* 95  2 83  2 .05
Restenosis (% free)* 87  3 61  5 .01
Clinical benefit (% retained)* 87  2 74  2 .05
*Mean  SEM at five years follow up.
Limb Ischemia During Femoral Cannulation for Cardiopulmonary
Support
Foley PJ, Morris RJ, Woo EY, Acker MA, Wang GJ, Jackson BM
Objectives: Extracorporeal membrane oxygenation and extracorporeal
cardiopulmonary support (ECMO/CPS) are potentially life-saving techniques
for patients with cardiopulmonary collapse. Complications include lower ex-
tremity ischemia from femoral cannulation. We examined the outcomes of
patients placed on ECMO/CPS, including the rate of limb ischemia.
Methods:All instances of ECMO/CPS over a three-year period (2006
to 2009) at a single university hospital were examined retrospectively for:
cannulation strategy, perfusion strategy, mortality, and limb ischemia. Po-
tential predictors of limb ischemia with femoral artery cannulation were age,
gender, body surface area (BSA), body mass index (BMI), and cannula size.
Results: Fifty-eight patients were placed on ECMO/CPS.Of these, 43
patients (74%) had femoral arterial cannulation. In 10 patients, the superfi-
cial femoral artery was cannulated prophylactically (without antecedent limb
ischemia), and perfused from a branch of the ECMO/CPS circuit. In seven
of the remaining 33 patients (21%), all male, limb ischemia developed,
requiring decannulation with fasciotomy (n  4) or additional cannulation
of the superficial femoral artery (SFA) with branching of the ECMO/CPS
circuit (n  3). One patient with ipsilateral leg ischemia required eventual
amputation. Patients with limb ischemia were significantly younger than
those who did not develop limb ischemia (P  .001). BSA, BMI, and
cannula size did not predict limb ischemia. Overall 30-day mortality follow-
ing the initiation of CPS/ECMO was 79%. There was no correlation
between limb ischemia and mortality.
Conclusions: Younger patients may be at increased risk for lower
extremity arterial insufficiency with femoral cannulation for ECMO/CPS.
Prophylactic or expectant SFA cannulation are reasonable approaches, and,
given that mortality does not increase with limb ischemia, SFA cannulation
from a branch of the circuit should be instituted liberally when required.
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without limb ischemia
Age
(years)
Male
Gender BSA (m2) BMI
Cannula
Size (Fr)
Mortality
(%)
Limb ischemia 36  18 7/7 2.09  0.29 29.5  10.0 16.9  1.1 4/7 (57)
No limb
ischemia
58  14 20/26 2.13  0.27 30.8  5.4 18.0  1.7 23/26 (88)
Prophylactic-Y 44  16 7/10 2.06  0.23 29.4  9.0 17.7  1.8 7/10 (70)
P-value* 0.001 0.30 0.57 0.65 0.09 0.09
BMI, Body mass index; BSA, body surface area.
*Between “limb ischemia” and “no limb ischemia” groups.
Does the Addition of Routine IVC/Iliac Vein and Infrapopliteal
Duplex Scan Confer any Benefit?
Alhabouni S, Hingorani A, Ascher E, et al
Objectives: The routine evaluation for lower extremity deep vein
thromboses (DVT) usually involves the femoral and popliteal veins with no
regard to the more proximal (Iliac and inferior vena cava [IVC]) veins or the
more distal (infra-popliteal) veins. In this study, we attempted to evaluate
the benefits of routine scanning of these segments.
Methods: We reviewed 1624 consecutive lower extremity venous
duplex studies performed for 1513 of our in-house patients between January
2008 and July 2008. All studies included routine evaluation of the IVC/iliac
and infra-popliteal vein segments. All studies were also evaluated for any
evidence of pulmonary embolism (PE).
Results: The IVC/iliac vein segments were completely evaluated in
1270 duplex studies with evidence of IVC/iliac vein DVTs in 37 (2.9%). In
354 studies, the evaluation was incomplete due to improper visualization of
the IVC mostly due to bowel gas. Despite that, evidence of iliac vein DVT
was noted in 18 (5.1%) of these studies. In total, the addition of routine iliac
vein/IVC duplex scan resulted in the detection of 55 (3.38%) DVTs with
evidence of PE in five (incidence of 9.1%). In five of those 55 duplex studies,
the IVC/iliac vein DVT was the only DVT detected, with evidence of PE in
one (incidence of 20%). The rest of the study population had evidence of
DVT in 244 studies (15.55%) with evidence of PE in 32 (incidence of
13.1%) of them (P  .59). Infra-popliteal segment: 145 infra-popliteal
DVTs were detected, of which 50 (34.5%) were isolated to the infra-
popliteal segments with evidence of PE in three (incidence of 6%). The rest
of the study population showed evidence of DVT in 98 with evidence of PE
in 14 (incidence of 14.3%) (P  .135).
Conclusions: Although routine scanning of the IVC/Iliac veins re-
sulted in detection rate of 3.38%, the detection of an isolated DVT in those
veins was very low (0.3%). However, isolated DVT of the iliac veins had a PE
rate of 20%. As for the routine scanning for infra-popliteal DVTs, 50
additional DVTs were detected with a PE rate of 6%, with no statistical
difference from the rate of PE from more proximal segments (P  .135).
Hence infra-popliteal DVTs should be regarded as risky as more proximal
DVTs and should therefore be treated similarly.
Mechanical-Chemical Endovenous Ablation: A New Tumescentless
Technique
Elias S
Objectives: The minimally invasive management of vein disease contin-
ues to evolve. Endothermal methods to ablate the great and small saphenous
veins involve the use of tumescent anesthesia for analgesia and compressionwith
possible adjunctive intravenous sedation. Foam sclerotherapy of the great and
small saphenous veins has been attempted with mixed results. A new en-
dovenous device that does not require tumescent anesthesia or intravenous
sedation, ClariVein (Vascular Insights LLC, Conn), was evaluated. The Clar-
iVein catheter utilizes endovenous mechanical vein wall destruction with a
rotating wire and the simultaneous infusion of a liquid sclerosant (Sotradecol)
to enhance venous ablation. This endovenous mechanical treatment is unique.
This Institutional Review Board-sanctioned study evaluated the safety and
efficacy of this technique.
Methods: The ClariVein device was utilized in 30 patients with great
saphenous vein incompetence. All procedures were performed in office with
only local anesthesia at the access site. No tumescent anesthesia or intrave-
nous sedation was employed. Ultrasound guidance similar to other en-
dovenous procedures was used. Post treatment care was similar to en-
dovenous thermal ablative procedures.
Results: Total procedure time was less than 15 minutes. Access was at
the lowest level of incompetence but no lower than below the knee. Results
at one week, one month, and three months will be presented including
occlusion rates greater than 90%. Complication rates and symptom resolu-
tion will be discussed.Conclusions: The unique endomechanical ablative aspect of the Clar-
iVein coupled with a safe FDA approved liquid sclerosant represents a furthersimplification and advancement in the treatment of venous disease. This is
accomplished without the tumescent anesthesia currently required for endo-
thermal methods and an early success rate comparable to these methods.
Endovenous Ablation plus Microphlebectomy/Sclerotherapy for the
Treatment of Varicose Veins: A Single or Two-Stage Procedure?
Schanzer H
Objectives: Endovenous ablation (EVA) of the saphenous vein has
almost completely replaced surgical stripping for the treatment of saphenous
vein reflux. In contrast to stripping that includes microphlebectomy, EVA is
generally performed in two stages (ablation followed, when needed, by
microphlebectomy or sclerotherapy). The purpose of this study was to
determine how often second stage procedures are required after EVA.
Methods: All consecutive patients undergoing laser EVA between
March 2007 andDecember 2008 were enrolled. At presentation, the clinical
severity of venous insufficiency was graded according to CEAP classification.
Patients were examined clinically/ultrasound at one week, and clinically at
one month. Varicose vein resolution following EVA was classified as excel-
lent (no varicosities), good (major reduction in size), and poor (no change).
Need for further intervention was determined at the one month follow-up.
Results: During the study period, 86 lower extremities in 76 patients
were treated with laser EVA (50 females, 26males, mean age 50 15 years).
By CEAP classification, 75 extremities were C2 (87.2%), five were C4
(5.8%), two were C5 (3.5%), and two were C6 (3.5%). Greater saphenous
veins were treated in 72 extremities (83.7%), small saphenous veins in 10
extremities (11.6%), anterior branch of the greater saphenous vein in two
extremities (2.3%), and both the greater saphenous vein and anterior branch
in two extremities (2.3%). The mean vein treatment length was 26.3  9.7
cm with a mean energy delivery of 64  11.3 Joules. At one week, all 86
extremities had the treated segment of vein closed and one of them had
partial extension of clot to the common femoral vein (1.16% incidence of
deep vein thrombosis [DVT]). At one month, complete resolution of
varicosities was found in 36 extremities (41.8%), reduction in size in 48
extremities (55.8%), and no improvement in two extremities (2.3%). Of the
patients with remaining varicosities, 15 extremities (17.4%) had small per-
sistent asymptomatic varicose veins of no concern to the patient. The
remaining 35 extremities (40.7%) required a second stage procedure.
Conclusions: After EVA, 59.3% of extremities did not require any
further treatment. These results justify the performance of EVA alone as a
first stage, as the majority of patients will be spared unnecessary microphle-
bectomy or sclerotherapy.
Evaluating the Availability of On-call Venous Duplex Scanning: ANew
Paradigm for Efficient Use of the Vascular Lab
Arnaoutakis G, Pirruccello J, Brooke B, Reifsnyder T
Objectives: Venous duplex ultrasound (VDU) is the standard evalua-
tion for acute deep vein thrombosis (DVT). Having the test available at all
hours imposes significant costs and universal availability may be unnecessary.
The purpose of this study was to compare the treatment and outcomes of
patients with suspectedDVT before (2005) and after (2007) eliminating the
availability of 24-hour VDU.
Methods: A retrospective cross-sectional study was performed among
patients evaluated by the emergency department (ED) for suspected DVT
during the years 2005 and 2007. The association of clinical variables, VDU
results, treatment, and complications were compared between time periods
using bivariate and multivariate regression models following propensity
score matching.
Results: In 2005 and 2007, 320 and 366 patients, respectively, had
VDU after referral by the ED. There were 31 acute DVTs in 2005 and 25 in
2007. There was no detected difference in thromboembolic complications.
Forty-nine (16%) tests during 2005 were done after hours. The number of
patients treated empirically before confirmation of DVT was significantly
higher in 2007: 51 (14%) vs 26 (8%) (P .019). Empiric treatment was also
more frequent in 2007 in patients confirmed to have acute DVT: seven
(28%) vs. three (7%) (P  .023). After matching patients by propensity
scores, regression models revealed a trend toward increased likelihood of
empiric treatment if patients had risk factor(s) known to indicate high risk for
DVT. There were no documented complications from empiric anti-coagu-
lation. Estimated savings for one year were $27,000.
Conclusions: The data suggest that elimination of around-the-clock
VDU services can render substantial savings to hospitals with no adverse
consequence in the acute management of DVT.
Long Term Functional Results of the Surgical Management of Neuro-
genic Thoracic Outlet Syndrome (NTOS)
Scali ST, Stone DH, Bjerke AA, Chang CK, Rzucidlo EM, Walsh DBObjectives: To document long-term functional outcomes in patients
treated for neurogenic thoracic outlet syndrome (NTOS).
